Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 546 | 63527-52-6 |
Dose | Unit | Route |
---|---|---|
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 30 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 376.38 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.60 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.20 hours | Lombardo F, Berellini G, Obach RS |
S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
March 11, 1981 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 235.81 | 27.61 | 94 | 5398 | 33742 | 63449788 |
Toxic epidermal necrolysis | 157.89 | 27.61 | 65 | 5427 | 25269 | 63458261 |
Eosinophilia | 123.74 | 27.61 | 53 | 5439 | 22703 | 63460827 |
Hepatocellular injury | 102.02 | 27.61 | 49 | 5443 | 27332 | 63456198 |
Premature baby | 89.24 | 27.61 | 41 | 5451 | 20694 | 63462836 |
Acute generalised exanthematous pustulosis | 88.34 | 27.61 | 34 | 5458 | 11065 | 63472465 |
Stevens-Johnson syndrome | 87.96 | 27.61 | 43 | 5449 | 24907 | 63458623 |
Rash maculo-papular | 83.55 | 27.61 | 45 | 5447 | 31851 | 63451679 |
Septic shock | 81.93 | 27.61 | 58 | 5434 | 66571 | 63416959 |
Pyrexia | 69.62 | 27.61 | 136 | 5356 | 470342 | 63013188 |
Purpura | 63.45 | 27.61 | 27 | 5465 | 11358 | 63472172 |
Multiple organ dysfunction syndrome | 61.99 | 27.61 | 46 | 5446 | 56706 | 63426824 |
Patent ductus arteriosus | 60.33 | 27.61 | 20 | 5472 | 4230 | 63479300 |
Agranulocytosis | 59.02 | 27.61 | 33 | 5459 | 25101 | 63458429 |
Fatigue | 55.98 | 27.61 | 6 | 5486 | 888022 | 62595508 |
Foetal exposure during pregnancy | 54.17 | 27.61 | 34 | 5458 | 31928 | 63451602 |
Laryngeal stenosis | 51.30 | 27.61 | 13 | 5479 | 1065 | 63482465 |
Hydrocephalus | 48.55 | 27.61 | 18 | 5474 | 5282 | 63478248 |
Umbilical erythema | 48.44 | 27.61 | 8 | 5484 | 72 | 63483458 |
Cholestasis | 44.16 | 27.61 | 29 | 5463 | 29405 | 63454125 |
Acute kidney injury | 42.30 | 27.61 | 79 | 5413 | 263336 | 63220194 |
Sepsis | 41.08 | 27.61 | 58 | 5434 | 153065 | 63330465 |
Necrosis | 40.78 | 27.61 | 16 | 5476 | 5471 | 63478059 |
Encephalopathy | 39.26 | 27.61 | 30 | 5462 | 38590 | 63444940 |
Subperiosteal abscess | 38.31 | 27.61 | 5 | 5487 | 5 | 63483525 |
Cross sensitivity reaction | 38.14 | 27.61 | 12 | 5480 | 2150 | 63481380 |
Thrombocytopenia | 37.25 | 27.61 | 55 | 5437 | 151102 | 63332428 |
Dermatitis bullous | 37.14 | 27.61 | 17 | 5475 | 8491 | 63475039 |
Epidermolysis | 36.35 | 27.61 | 9 | 5483 | 670 | 63482860 |
Lactic acidosis | 35.14 | 27.61 | 28 | 5464 | 38259 | 63445271 |
Ventricular dysfunction | 34.97 | 27.61 | 12 | 5480 | 2816 | 63480714 |
Disseminated intravascular coagulation | 34.13 | 27.61 | 21 | 5471 | 19030 | 63464500 |
Dysbiosis | 33.78 | 27.61 | 9 | 5483 | 897 | 63482633 |
Arthralgia | 33.02 | 27.61 | 5 | 5487 | 569705 | 62913825 |
Petechiae | 31.94 | 27.61 | 18 | 5474 | 13879 | 63469651 |
Toxic shock syndrome streptococcal | 31.83 | 27.61 | 6 | 5486 | 121 | 63483409 |
Pulmonary necrosis | 31.33 | 27.61 | 6 | 5486 | 132 | 63483398 |
Central nervous system necrosis | 30.80 | 27.61 | 6 | 5486 | 145 | 63483385 |
Haemophagocytic lymphohistiocytosis | 30.65 | 27.61 | 16 | 5476 | 10611 | 63472919 |
Stenotrophomonas infection | 30.62 | 27.61 | 10 | 5482 | 2017 | 63481513 |
Clostridium bacteraemia | 28.94 | 27.61 | 6 | 5486 | 200 | 63483330 |
Necrotising enterocolitis neonatal | 28.68 | 27.61 | 6 | 5486 | 209 | 63483321 |
Oligohydramnios | 28.67 | 27.61 | 13 | 5479 | 6353 | 63477177 |
Cyanosis | 28.64 | 27.61 | 18 | 5474 | 16917 | 63466613 |
Hepatic failure | 28.37 | 27.61 | 24 | 5468 | 35632 | 63447898 |
Respiratory acidosis | 28.00 | 27.61 | 13 | 5479 | 6702 | 63476828 |
Toxic skin eruption | 27.76 | 27.61 | 16 | 5476 | 12869 | 63470661 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 366.90 | 22.70 | 160 | 6457 | 32852 | 34917462 |
Hepatocellular injury | 169.24 | 22.70 | 83 | 6534 | 22128 | 34928186 |
Rash maculo-papular | 163.74 | 22.70 | 88 | 6529 | 28363 | 34921951 |
Toxic epidermal necrolysis | 116.28 | 22.70 | 64 | 6553 | 21582 | 34928732 |
Eosinophilia | 97.24 | 22.70 | 61 | 6556 | 26161 | 34924153 |
Clostridium difficile colitis | 83.05 | 22.70 | 46 | 6571 | 15684 | 34934630 |
Haemophagocytic lymphohistiocytosis | 74.18 | 22.70 | 40 | 6577 | 12933 | 34937381 |
Cholestasis | 69.38 | 22.70 | 50 | 6567 | 26898 | 34923416 |
Hepatic cytolysis | 67.36 | 22.70 | 39 | 6578 | 14457 | 34935857 |
Agranulocytosis | 63.16 | 22.70 | 45 | 6572 | 23776 | 34926538 |
Acute kidney injury | 56.54 | 22.70 | 155 | 6462 | 304833 | 34645481 |
Purpura | 51.27 | 22.70 | 29 | 6588 | 10282 | 34940032 |
Toxic skin eruption | 51.22 | 22.70 | 30 | 6587 | 11355 | 34938959 |
Urethral valves | 47.52 | 22.70 | 11 | 6606 | 275 | 34950039 |
Acute generalised exanthematous pustulosis | 44.71 | 22.70 | 23 | 6594 | 6753 | 34943561 |
Pyrexia | 44.54 | 22.70 | 151 | 6466 | 332862 | 34617452 |
Klebsiella infection | 39.74 | 22.70 | 23 | 6594 | 8508 | 34941806 |
Dermatitis bullous | 38.60 | 22.70 | 21 | 6596 | 6901 | 34943413 |
Neutropenia | 37.59 | 22.70 | 88 | 6529 | 156690 | 34793624 |
Thrombotic microangiopathy | 37.54 | 22.70 | 24 | 6593 | 10606 | 34939708 |
Vasculitis necrotising | 36.03 | 22.70 | 11 | 6606 | 809 | 34949505 |
Mixed liver injury | 35.32 | 22.70 | 15 | 6602 | 2858 | 34947456 |
Drug ineffective | 34.74 | 22.70 | 174 | 6443 | 456577 | 34493737 |
Thrombocytopenia | 33.49 | 22.70 | 84 | 6533 | 156163 | 34794151 |
Death | 31.83 | 22.70 | 18 | 6599 | 398031 | 34552283 |
Fatigue | 30.73 | 22.70 | 16 | 6601 | 370637 | 34579677 |
Serratia sepsis | 29.27 | 22.70 | 6 | 6611 | 83 | 34950231 |
Off label use | 29.20 | 22.70 | 156 | 6461 | 419368 | 34530946 |
Nausea | 29.18 | 22.70 | 14 | 6603 | 339894 | 34610420 |
Pancytopenia | 29.14 | 22.70 | 59 | 6558 | 95098 | 34855216 |
ADAMTS13 activity decreased | 28.88 | 22.70 | 6 | 6611 | 89 | 34950225 |
Systemic candida | 28.55 | 22.70 | 14 | 6603 | 3712 | 34946602 |
Red blood cell schistocytes present | 28.17 | 22.70 | 7 | 6610 | 238 | 34950076 |
Respiratory gas exchange disorder | 28.05 | 22.70 | 8 | 6609 | 464 | 34949850 |
Bicytopenia | 27.83 | 22.70 | 12 | 6605 | 2372 | 34947942 |
Septic shock | 27.51 | 22.70 | 49 | 6568 | 71785 | 34878529 |
Rash | 27.05 | 22.70 | 98 | 6519 | 222654 | 34727660 |
Haematoma muscle | 26.80 | 22.70 | 10 | 6607 | 1358 | 34948956 |
Abscess | 26.07 | 22.70 | 20 | 6597 | 11797 | 34938517 |
Gamma-glutamyltransferase increased | 24.62 | 22.70 | 29 | 6588 | 29202 | 34921112 |
Face oedema | 24.34 | 22.70 | 19 | 6598 | 11497 | 34938817 |
CD4 lymphocytes increased | 23.71 | 22.70 | 6 | 6611 | 220 | 34950094 |
Serratia infection | 23.04 | 22.70 | 8 | 6609 | 884 | 34949430 |
Cross sensitivity reaction | 23.02 | 22.70 | 9 | 6608 | 1388 | 34948926 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 602.40 | 23.07 | 249 | 10338 | 63995 | 79669806 |
Hepatocellular injury | 264.12 | 23.07 | 128 | 10459 | 47465 | 79686336 |
Rash maculo-papular | 252.83 | 23.07 | 131 | 10456 | 55947 | 79677854 |
Toxic epidermal necrolysis | 250.69 | 23.07 | 121 | 10466 | 44460 | 79689341 |
Eosinophilia | 224.91 | 23.07 | 113 | 10474 | 45232 | 79688569 |
Agranulocytosis | 126.00 | 23.07 | 77 | 10510 | 44953 | 79688848 |
Purpura | 115.73 | 23.07 | 55 | 10532 | 19472 | 79714329 |
Acute generalised exanthematous pustulosis | 109.66 | 23.07 | 51 | 10536 | 17203 | 79716598 |
Pyrexia | 107.01 | 23.07 | 260 | 10327 | 678449 | 79055352 |
Cholestasis | 106.14 | 23.07 | 73 | 10514 | 52036 | 79681765 |
Acute kidney injury | 92.64 | 23.07 | 209 | 10378 | 519195 | 79214606 |
Clostridium difficile colitis | 92.33 | 23.07 | 56 | 10531 | 32227 | 79701574 |
Hepatic cytolysis | 87.84 | 23.07 | 51 | 10536 | 27100 | 79706701 |
Stevens-Johnson syndrome | 82.42 | 23.07 | 56 | 10531 | 39110 | 79694691 |
Toxic skin eruption | 80.52 | 23.07 | 45 | 10542 | 22248 | 79711553 |
Septic shock | 80.32 | 23.07 | 90 | 10497 | 122711 | 79611090 |
Haemophagocytic lymphohistiocytosis | 75.94 | 23.07 | 43 | 10544 | 21794 | 79712007 |
Fatigue | 73.27 | 23.07 | 17 | 10570 | 929710 | 78804091 |
Dermatitis bullous | 72.01 | 23.07 | 36 | 10551 | 14209 | 79719592 |
Thrombocytopenia | 67.68 | 23.07 | 124 | 10463 | 265135 | 79468666 |
Neutropenia | 57.04 | 23.07 | 121 | 10466 | 287589 | 79446212 |
Pain | 55.11 | 23.07 | 13 | 10574 | 703789 | 79030012 |
Cross sensitivity reaction | 54.58 | 23.07 | 20 | 10567 | 3692 | 79730109 |
Encephalopathy | 53.92 | 23.07 | 55 | 10532 | 67342 | 79666459 |
Multiple organ dysfunction syndrome | 51.06 | 23.07 | 71 | 10516 | 120175 | 79613626 |
Mixed liver injury | 50.01 | 23.07 | 23 | 10564 | 7555 | 79726246 |
Nausea | 48.67 | 23.07 | 34 | 10553 | 957162 | 78776639 |
Pseudomembranous colitis | 47.40 | 23.07 | 20 | 10567 | 5354 | 79728447 |
Laryngeal stenosis | 45.65 | 23.07 | 13 | 10574 | 1075 | 79732726 |
Thrombotic microangiopathy | 42.80 | 23.07 | 29 | 10558 | 20140 | 79713661 |
Arthralgia | 40.16 | 23.07 | 13 | 10574 | 571790 | 79162011 |
Hyperbilirubinaemia | 39.92 | 23.07 | 30 | 10557 | 24488 | 79709313 |
Red blood cell schistocytes present | 38.59 | 23.07 | 10 | 10577 | 579 | 79733222 |
Epidermolysis | 38.08 | 23.07 | 11 | 10576 | 957 | 79732844 |
Hydrocephalus | 34.97 | 23.07 | 19 | 10568 | 8881 | 79724920 |
Vasculitis necrotising | 34.88 | 23.07 | 11 | 10576 | 1289 | 79732512 |
Anaphylactic shock | 33.66 | 23.07 | 32 | 10555 | 35964 | 79697837 |
Bicytopenia | 33.42 | 23.07 | 15 | 10572 | 4655 | 79729146 |
Klebsiella infection | 31.92 | 23.07 | 22 | 10565 | 15698 | 79718103 |
Subperiosteal abscess | 28.88 | 23.07 | 5 | 10582 | 38 | 79733763 |
Hepatic failure | 28.78 | 23.07 | 38 | 10549 | 61174 | 79672627 |
Pancytopenia | 28.59 | 23.07 | 66 | 10521 | 165679 | 79568122 |
Enterococcal infection | 27.37 | 23.07 | 20 | 10567 | 15640 | 79718161 |
Ventricular dysfunction | 26.89 | 23.07 | 14 | 10573 | 6009 | 79727792 |
ADAMTS13 activity decreased | 26.79 | 23.07 | 6 | 10581 | 186 | 79733615 |
Respiratory gas exchange disorder | 26.20 | 23.07 | 8 | 10579 | 843 | 79732958 |
Serratia sepsis | 26.04 | 23.07 | 6 | 10581 | 212 | 79733589 |
Off label use | 25.90 | 23.07 | 207 | 10380 | 907008 | 78826793 |
Rash | 24.83 | 23.07 | 146 | 10441 | 578212 | 79155589 |
Brain oedema | 24.66 | 23.07 | 23 | 10564 | 25240 | 79708561 |
Central nervous system necrosis | 24.27 | 23.07 | 6 | 10581 | 287 | 79733514 |
Gamma-glutamyltransferase increased | 24.26 | 23.07 | 33 | 10554 | 54647 | 79679154 |
CD4 lymphocytes increased | 24.17 | 23.07 | 6 | 10581 | 292 | 79733509 |
Haematoma muscle | 23.96 | 23.07 | 10 | 10577 | 2605 | 79731196 |
Neutrophil count increased | 23.52 | 23.07 | 24 | 10563 | 29372 | 79704429 |
Nasopharyngitis | 23.49 | 23.07 | 3 | 10584 | 253878 | 79479923 |
HIV associated nephropathy | 23.44 | 23.07 | 6 | 10581 | 331 | 79733470 |
None
Source | Code | Description |
---|---|---|
ATC | J01DD01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
ATC | J01DD51 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Streptococcal meningitis | indication | 4510004 | DOID:11574 |
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Streptococcal septicemia | indication | 29577008 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Neonatal conjunctivitis | indication | 34298002 | DOID:9699 |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Bacterial arthritis | indication | 48245008 | |
Peritonitis | indication | 48661000 | |
Lower respiratory tract infection | indication | 50417007 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Bacterial infection due to Serratia | indication | 71120004 | |
Septicemia due to Serratia | indication | 82091000 | |
Bacterial meningitis | indication | 95883001 | DOID:9470 |
Infection of bone | indication | 111253001 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Meningococcal meningitis | indication | 192644005 | |
Escherichia coli meningitis | indication | 192655005 | |
Proteus pneumonia | indication | 195888009 | |
Sepsis of the newborn | indication | 206376005 | |
Neonatal pneumonia | indication | 233619008 | |
Neonatal meningitis | indication | 276674008 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial urinary infection | indication | 312124009 | |
Meningitis due to Klebsiella mobilis | indication | 420585007 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Cesarean Section Infection Prevention | indication | ||
Streptococcal Peritonitis | indication | ||
E. Coli Peritonitis | indication | ||
E. Coli Endometritis | indication | ||
Haemophilus Influenzae Type B Infections | indication | ||
Neonatal Group B Streptococcal Septicemia | indication | ||
Klebsiella Endometritis | indication | ||
Proteus Endometritis | indication | ||
Enterococcus Pelvic Cellulitis | indication | ||
Prevention of Perioperative Infection | indication | ||
Proteus Mirabilis Osteomyelitis | indication | ||
Bacteroides Pelvic Cellulitis | indication | ||
Klebsiella Pelvic Inflammatory Disease | indication | ||
Staphylococcus Endometritis | indication | ||
H. Influenzae Meningitis | indication | ||
Clostridium Pelvic Inflammatory Disease | indication | ||
Haemophilus Parainfluenzae Pneumonia | indication | ||
Bacteroides Pelvic Inflammatory Disease | indication | ||
Staphylococcus Pelvic Inflammatory Disease | indication | ||
Proteus Peritonitis | indication | ||
Clostridium Endometritis | indication | ||
Staphylococcus Epidermidis Urinary Tract Infection | indication | ||
Enterococcus Pelvic Inflammatory Disease | indication | ||
Morganella Morganii Urinary Tract Infection | indication | ||
Fusobacterium Pelvic Inflammatory Disease | indication | ||
Streptococcus Osteomyelitis | indication | ||
Enterococcus Urinary Tract Infection | indication | ||
Clostridium Pelvic Cellulitis | indication | ||
Serratia Urinary Tract Infection | indication | ||
Enterobacter Pneumonia | indication | ||
Enterobacter Pelvic Inflammatory Disease | indication | ||
Bacteroides Endometritis | indication | ||
Providencia Urinary Tract Infection | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Fusobacterium Endometritis | indication | ||
Proteus Pelvic Inflammatory Disease | indication | ||
Clostridium Peritonitis | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
E. Coli Pelvic Cellulitis | indication | ||
Enterobacter Endometritis | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Enterococcus Endometritis | indication | ||
Pyrexia of unknown origin | off-label use | 7520000 | |
Acute gonococcal cervicitis | off-label use | 20943002 | DOID:10615 |
Lyme disease | off-label use | 23502006 | DOID:11729 |
Acute gonococcal urethritis | off-label use | 29864006 | |
Lyme arthritis | off-label use | 33937009 | |
Pseudotuberculosis | off-label use | 36753006 | |
Gonorrhea of rectum | off-label use | 42746002 | |
Lyme carditis | off-label use | 77863005 | |
Infection by Yersinia enterocolitica | off-label use | 80960004 | |
Ventilator-acquired pneumonia | off-label use | 429271009 | |
Disseminated Gonococcal Infection | off-label use | ||
Lyme Disease of the Central Nervous System | off-label use | ||
Acute nephropathy | contraindication | 58574008 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.39 | acidic |
pKa2 | 13.31 | acidic |
pKa3 | 3.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 6.24 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 6.51 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 5.66 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 2 | Enzyme | INHIBITOR | IC50 | 4.62 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | Ki | 6.30 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.60 | CHEMBL |
ID | Source |
---|---|
4019663 | VUID |
N0000147755 | NUI |
D00919 | KEGG_DRUG |
64485-93-4 | SECONDARY_CAS_RN |
203117 | RXNORM |
C0007554 | UMLSCUI |
CHEBI:3498 | CHEBI |
CE3 | PDB_CHEM_ID |
CHEMBL1010 | ChEMBL_ID |
CHEMBL1730 | ChEMBL_ID |
D002439 | MESH_DESCRIPTOR_UI |
DB00493 | DRUGBANK_ID |
10893 | IUPHAR_LIGAND_ID |
4504 | INN_ID |
N2GI8B1GK7 | UNII |
10695961 | PUBCHEM_CID |
42787 | MMSL |
4378 | MMSL |
d00008 | MMSL |
002727 | NDDF |
004845 | NDDF |
3334000 | SNOMEDCT_US |
372704003 | SNOMEDCT_US |
41722006 | SNOMEDCT_US |
4018466 | VANDF |
4019663 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9930 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9931 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9933 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9935 | INJECTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-011 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-011 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-012 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21586-012 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | Unapproved drug for use in drug shortage | 2 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-947 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 11 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-948 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 11 sections |
CEFOTAXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-986 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 11 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-947 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 20 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-948 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 20 sections |
Cefotaxime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-986 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |